Trading bluebird bio to $6:

NASDAQ:BLUE   bluebird bio, Inc.
Bluebird bio (BLUE) is a biotech company focused on developing and commercializing gene and cell therapies to treat genetic diseases. Lead asset LentiGlobin (Zynteglo) is approved in US and Europe for the treatment of transfusion-dependent thalassemia. Bluebird's LentiGlobin (lovo-cel) is also in pre-registrational stage for sickle cell disease.

Bluebird is also right behind Crispr and Vertex in pursuit of a sickle cell approval.

June 21st 2023: Lovo-cel is a potentially transformative one-time gene therapy for individuals living with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events. It is specifically designed to treat the underlying cause of SCD through the addition of a functional gene that enables production of anti-sickling adult hemoglobin and is the most deeply studied gene therapy in development for this disease. The agency has set a Prescription Drug User Fee Act goal date of December 20, 2023.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.